Soefiandi Soedarman

Dr. Soefiandi Soedarman

JEC Eye Hospitals & Clinics, Jakarta, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Vision
Verified
Journal Article
Open access
PDF file
SSSoefiandi Soedarman
Soefiandi Soedarman
KKKing Hans Kurnia
King Hans Kurnia
APAlberthus Donni Budi Prasetya
Alberthus Donni Budi Prasetya
MSMuhammad Bayu Sasongko
Muhammad Bayu Sasongko
Serum apolipoproteins have been reported as a more significant marker for diabetic retinopathy (DR) compared with serum cholesterols. This article aims to review the associations between serum cholesterols and apolipoproteins, and the presence and severity of DR. The protocol of this systematic review was registered at the PROSPERO registry (CRD42022303331). We conducted a systematic search of literature published between 2011 to 2022 using the search terms “serum cholesterol” AND/OR “lipoprotein” AND/OR “apolipoprotein” AND/OR “diabetic retinopathy”. Fifteen studies were included in this review. Six studies assessed the association between serum cholesterols, apolipoproteins, and the presence of DR. Three studies reported lower levels of apolipoprotein A1, and one study reported higher levels of apolipoprotein B in patients with DR. The remaining nine studies compared serum cholesterol and apolipoprotein levels according to DR severity. Patients with more severe grades of DR presented with lower apolipoprotein A1 in six (66.7%) studies, higher apolipoprotein B levels in seven (77.8%) studies, and a higher apolipoprotein B/apolipoprotein A1 ratio in six out of seven (85%) studies. In conclusion, serum apolipoproteins, in particular the apolipoprotein B/apolipoprotein A1 ratio, were a more consistent marker for DR severity compared with serum cholesterols.

27 June 2023 in BMJ Open Ophthalmology
Verified
Journal Article
Open access
PDF file
SSSoefiandi Soedarman
Soefiandi Soedarman
MJMadarina Julia
Madarina Julia
TGTjahjono D Gondhowiardjo
Tjahjono D Gondhowiardjo
APAlberthus Donni Budi Prasetya
Alberthus Donni Budi Prasetya
KKKing Hans Kurnia
King Hans Kurnia
MSMuhammad Bayu Sasongko
Muhammad Bayu Sasongko
Aims To investigate the associations of baseline apolipoprotein A1 (ApoA1) and B (ApoB) levels with persistent and incident diabetic macular oedema (DMO) after 6 months of follow-up. Methods This is a prospective cohort study of patients aged ≥30 years with untreated diabetic retinopathy. Examinations, fundus photography and spectral domain optical coherence tomography (SD-OCT) were assessed at baseline, 1, 3 and 6 months. Serum lipids and apolipoproteins were analysed at a pathology laboratory. DMO was confirmed using SD-OCT, classified as (1) incident DMO, (2) persistent DMO and (3) regressed DMO. Eye-specific data were used, controlling for covariates and cluster effect. Results We recruited 53 patients but only 38 completed the study [(62 eyes), 20 eyes (32.3%) with DMO]. Higher quartile of ApoA1 was associated with lower risk of persistent/incident DMO (p for trend 0.02), while higher ApoB/A1 was associated with higher risk of persistent/incident DMO (p for trend 0.02). Every 10 mg/dL increase in ApoA1 levels was associated with lower risk of persistent/incident DMO (OR 0.69; 95% CI 0.49 to 0.92; p value 0.016), whereas every 0.2 increase in ApoB/A1 was significantly associated with higher risk of persistent/incident DMO (OR 1.4; 95% CI 1.1 to 1.9; p value 0.013) at the end of the study. Conclusion Individuals with diabetes with higher ApoA1 had lower risk of persistent/incident DMO and those with higher ApoB/A1 had higher risk of persistent/incident DMO at the end of 6 months. These suggest that serum ApoA1 and ApoB/A1 levels may be important risk factors for DMO and could be predictive of persistent/incident DMO despite anti-vascular endothelial growth factor treatment.

9 July 2025
Verified
Journal Article
Open access
SSSoefiandi Soedarman
Soefiandi Soedarman
MJMadarina Julia
Madarina Julia
TGTjahjono Darminto Gondhowiardjo
Tjahjono Darminto Gondhowiardjo
KKKing Hans Kurnia
King Hans Kurnia
APAlberthus Donni Budi Prasetya
Alberthus Donni Budi Prasetya
MSMuhammad Bayu Sasongko
Muhammad Bayu Sasongko
This study aimed to explore the relationships between serum apolipoprotein A1 (ApoA1) and B (ApoB) levels and the ApoB/A1 ratio with structural and vascular changes in the retinas of patients with diabetic macular edema (DME), as assessed through optical coherence tomography (OCT) and OCT angiography (OCTA). 62 eyes from 38 treatment-naive diabetic retinopathy patients were assessed. Baseline and 6-month evaluations included clinical exams, fundus photography, blood tests for cholesterol, ApoA1, and ApoB, as well as imaging with OCT and OCTA. Associations between apolipoproteins and changes in central retinal thickness (CRT), foveal avascular zone (FAZ), and vessel/perfusion density were analyzed. In DME patients, elevated ApoB levels (>122.5 mg/dL) were significantly linked with increased CRT, FAZ expansion, and reduced perfusion density at the 6-month follow-up (p = 0.026, 0.046, and 0.025). Higher ApoB/A1 ratio (>0.85) was significantly associated with decreased perfusion density (p = 0.011). Elevated ApoB levels and ApoB/A1 ratio were linked with reduced perfusion and vessel density, increased CRT, and FAZ expansion, highlighting their potential as negative biomarkers for OCT-detected retinomacular changes.

22 May 2025 in Vision
Verified
Journal Article
Open access
PDF file
SSSoefiandi Soedarman
Soefiandi Soedarman
SMSandi Muslim
Sandi Muslim
WGWaldensius Girsang
Waldensius Girsang
ELElvioza
Elvioza
RAReferano Agustiawan
Referano Agustiawan
ITIchsan Fauzi Triyoga
Ichsan Fauzi Triyoga
Macular hole (MH) surgery generally has a high success rate, but finding anatomical plug for refractory cases remains challenging. The human amniotic membrane (hAM), with its anti-inflammatory and regenerative properties, has emerged as a potential option. This study aims to report the anatomical and functional outcomes of human amniotic membrane (hAM) graft as an intervention to repair refractory macular hole cases where wide internal limiting membrane (ILM) peeling was unsuccessful. A retrospective chart review was conducted at a single center, with the main outcomes being closure rate and postoperative BCVA at 6 months. Eleven eyes of 11 patients with refractory macular holes were identified and included in the study. Participants were predominantly males (72.73%) with a mean age of 49.27 years. Nine eyes achieved successful MH closure with a single intervention and showed no recurrence during the 6-month follow-up. Mean BCVA at 3 and 6 months improved significantly (p = 0.0207) from 1.747 ± 0.74 logMAR to 1.210 ± 0.51 logMAR and 0.939 ± 0.47 logMAR (range 2.079–0.301 logMAR). The use of human amniotic membrane (hAM) graft seems to be a viable and effective alternative for the treatment of refractory macular holes. However, further larger prospective controlled studies are necessary to confirm our results.